SCHEMBL6084057

SCHEMBL6084057

O=C(Cc1ccc(Cl)cc1)Nc1ccc(-c2n[nH]cc2-c2nc3ccccc3o2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.58
THRB P10828 2/20 0.58
CSNK1D P48730 1/20 0.56
MAPT P10636 1/20 0.55
KDR P35968 4/20 0.54
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 1/20 0.53
PPARG P37231 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NR2E3 Q9Y5X4 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
RXFP1 Q9HBX9 1/20 0.52
P2RY14 Q15391 2/20 0.51
CETP P11597 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086143 0.92 HSD17B10 (0.53) TP53THRBMAPTKDM4EALDH1A1
SCHEMBL6086216 0.91 P2RY14 (0.63) TP53THRBMAPTKDRSMN1; SMN2
SCHEMBL6084737 0.89 TP53 (0.64) TP53THRBMAPTKDRKDM4E
SCHEMBL6085820 0.85 MAPT (0.47) TP53THRBMAPTKDM4EALDH1A1
SCHEMBL6084498 0.85 TP53 (0.56) TP53THRBMAPTKDRKDM4E
SCHEMBL6085230 0.83 CETP (0.63) TP53THRBMAPTP2RY14CETP
SCHEMBL6084815 0.82 MAPT (0.53) TP53THRBMAPTKDM4EALDH1A1
SCHEMBL6086921 0.82 MAPT (0.53) TP53THRBMAPTKDM4EALDH1A1
SCHEMBL6084754 0.82 MAPT (0.67) TP53MAPTKDRKDM4EALDH1A1
SCHEMBL6085104 0.81 AGPAT2 (0.51) TP53THRBMAPTKDRRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 TP53 466/4885THRB 1963/4885CSNK1D 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.